Skip to main content Start of content

HESA Committee Meeting

Notices of Meeting include information about the subject matter to be examined by the committee and date, time and place of the meeting, as well as a list of any witnesses scheduled to appear. The Evidence is the edited and revised transcript of what is said before a committee. The Minutes of Proceedings are the official record of the business conducted by the committee at a sitting.

For an advanced search, use Publication Search tool.

If you have any questions or comments regarding the accessibility of this publication, please contact us at accessible@parl.gc.ca.

Previous day publication Next day publication

Minutes of Proceedings

42nd Parliament, 1st Session
Meeting 112
Thursday, September 27, 2018, 8:45 a.m. to 10:43 a.m.
In Camera
Presiding
Bill Casey, Chair (Liberal)

Library of Parliament
• Karin Phillips, Analyst
• Marlisa Tiedemann, Analyst
The Committee proceeded to the consideration of matters related to Committee business.

It was agreed, — That the proposed budget in the amount of $15,300, for the study on the barriers to access to treatment and drugs for Canadians affected by rare diseases and disorders, be adopted.

It was agreed, — That, in relation to the study of federally funded health research (M-132), Members submit their prioritized lists of witnesses to the Clerk by Wednesday, October 3, 2018, at 4:00 p.m..

It was agreed, — That, in relation to the study on the barriers to access to treatment and drugs for Canadians affected by rare diseases and disorders, Members submit their prioritized lists of witnesses for a panel on international best practices to the Clerk by Wednesday, October 3, 2018, at 4:00 p.m.

At 8:59 a.m., the sitting was suspended.

At 9:01 a.m., the sitting resumed in public.

Amyotrophic Lateral Sclerosis Society of Canada
• Tammy Moore, Chief Executive Officer
Department of Health
• Catherine Parker, Director General, Biologics and Genetic Therapies Directorate, Health Products and Food Branch
• Karen Reynolds, Executive Director, Office of Pharmaceuticals Management Strategies
• John Patrick Stewart, Director General, Therapeutic Products Directorate
Canadian Organization for Rare Disorders
• Maureen Smith, Board Secretary
• Durhane Wong-Rieger, President and Chief Executive Officer
Pursuant to Standing Order 108(2) and the motion adopted by the Committee on Wednesday, April 18, 2018, the Committee commenced its study on barriers to access to treatment and drugs for Canadians affected by rare diseases and disorders.

Catherine Parker made a statement and, with John Patrick Stewart and Karen Reynolds, answered questions.

At 9:44 a.m., the sitting was suspended.

At 9:47 a.m., the sitting resumed.

Durhane Wong-Rieger, Maureen Smith and Tammy Moore made statements and answered questions.

At 10:43 a.m., the Committee adjourned to the call of the Chair.



Marie-Hélène Sauvé
Clerk of the Committee